Redeye retains its positive view on BIMobject despite lowering its forecasts and Base case. Q1 highlighted the significant cost reductions, and while the ARR was flat q/q, we believe sales growth will accelerate from now on for several reasons. Combined with limited cost increases, we believe BIMobject is heading for a cash flow neutral 2022 and a profitable 2023.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BIMobject - Shifting focus to sales growth

© Modular Finance, source Nordic Press Releases